Technology FAQs

The CAR targets are neo-antigens present on the cell surface of adenocarcinomas and more than 90% of ovarian cancer cells. T cells or NK cells with this CAR will seek and bind to the targeted cancer cells via the CAR and signal the immune cell to kill these dangerous cells. We are also researching how […]

Cartherics has an autologous CAR-T product treating ovarian cancer, entering clinical trials in 2025-26. The lead allogeneic product is expected to enter clinical trials for ovarian cancer in 2026-27. The product pipeline focuses on disruption of the tumour microenvironment enabling access and longevity of CAR-immune cell attack and establishment of memory immune surveillance. We are […]

The Cartherics allogeneic (off-the-shelf) technology is based on umbilical cord blood cells from rare histocompatibility donors that are converted to stem cells (iPSCs) and gene edited to introduce CARs and to knock-out genes that inhibit immune function. The products are complex versions of the patient’s immune cells altered to aggressively attack solid tumours and endometriosis. […]

Chimeric antigen receptors (CARs) are antibody fragments linked to activation molecules, that recognise molecules specifically present on the surface of cancer cells. These CAR complexes are genetically engineered into the immune cell (T cell or NK cell) genome and expressed on their surface. When the antibody fragment engages with the cancer cell, the activation molecules […]